Digoxin & Gender
Digoxin
is a very commonly prescribed drug, and is used to improve the function
of chronically failing hearts, and for controlling the heart rate in
the case of certain cardiac rhythm disturbances. In patients with congestive
heart failure (CHF), digoxin improves the strength of heart muscle contractions.
Digoxin is derived from the leaves of the foxglove plant (Digitalis
purpurea), and has been prescribed in one form or another since
the 18th century.
A newly published study in the New
England Journal of Medicine calls into question the effectiveness
of this venerable heart medication. The so-called “Digitalis Investigation
Group” study looked at 6,800 patients with CHF. Among men with CHF,
the use of digoxin appeared to have no effect on overall death rates
when compared with men who were given a placebo (“sugar pill”). Interestingly,
women who took digoxin experienced a 23 percent increase in the overall
rate of death when compared to women taking placebo pills.
Although this study found a slight reduction
in the number of hospital visits associated with the use of digoxin
by CHF patients, the lack of improvement in the overall death rate for
men taking the drug is disappointing news. At the same time, the increased
risk of death associated with digoxin use in women with CHF is worrisome.
This is the first study to show such a gender-specific difference in
the effects of digoxin, although the reasons for this observation are
unclear at this time. This study would appear to generally call into
question the benefits of digoxin in the treatment of CHF, particularly
among women. However, if you are currently taking digoxin for a heart
condition, please do not arbitrarily stop taking this medication. I
would recommend, instead, that you visit with your doctor, and discuss
this study and its implications. Additional studies will have to be
done to confirm this study’s novel findings. Meanwhile, digoxin may
have already lost some of its therapeutic luster.
Driving & Degenerative Disc Disease
Chronic low back pain is extremely common
in industrialized nations, and is the most common cause for workman’s
compensation claims. Professional drivers, such as truck and taxi drivers,
have long been thought to be at increased risk for developing lumbar
disc degeneration. The intervertebral discs are tough fibrous rings
that serve as shock absorbers for the spine. It has been assumed that
prolonged sitting, and vibration transmitted to the spine’s natural
shock absorbers, play a key role in this increased risk of spinal disc
disease among drivers. However, a new study in the journal Lancet
appears to suggest otherwise.
In an interesting study, 45 pairs of
identical male twins were studied in Finland. The twin pairs were especially
selected in that one of the two twins in each pair was a driver by occupation
while the other twin was not. Driving histories were obtained for all
study participants, and spinal disc degeneration was assessed by MRI
scans. The study failed to identify any difference in the incidence
of spinal disc degeneration between the brothers who were professional
drivers and their non-driver twins. The study’s authors conclude that
prolonged driving can exacerbate preexisting back conditions, but does
not appear to cause or contribute to degenerative changes in the spinal
discs.
Coenzyme Q10 & Parkinson’s
Disease
Parkinson’s disease (PD) is an incurable
neurological disorder that results from the deterioration and death
of dopamine-producing cells in a part of the brain called the substantia
nigra. Patients with PD develop progressive difficulties in initiating
movements. PD also causes tremors of the hands and, in some cases,
dementia similar to that which occurs in patients with Alzheimer’s disease.
Some of the lost dopamine can be replaced or scavenged in the brains
of patients with PD with drugs. More recently, transplantation of substantia
nigra cells from fetal brain tissue has been attempted with variable
degrees of success (and considerable ethical controversy).
In the current issue of the Archives
of Neurology, the effects of coenzyme Q10 on early PD
were studied in 80 patients over a period of 16 months. Coenzyme Q10
is a naturally occurring substance in the body that plays a critical
role in energy metabolism, and also has antioxidant properties as well.
In this study, coenzyme Q10, when given in higher doses (up
to 1,200 mg per day), significantly slowed the progression of PD-related
movement disorders. This is an intriguing study, and it is consistent
with other studies that have shown beneficial effects in patients with
early PD who were taking high doses of antioxidants, including vitamins
C and E. High doses of antioxidant compounds appear to slow the loss
of substantia nigra cells in PD patients who are in the early stages
of this disease. Further study of this phenomenon and the effects of
coenzyme Q10 in particular, should be studied on a larger
scale, as this pilot study only looked at 80 patients. However, this
small study may offer some hope to the approximately one million Americans
who suffer from the devastating effects of PD.
Ginseng & Erections
Ginseng has been used in many Asian
countries for centuries to cure a variety of ills, including impotence.
However, previous scientific studies have not been able to demonstrate
any specific therapeutic effects associated with ginseng consumption.
A study reported in the current issue of the Journal of Urology
might change this perception of ginseng, however.
A total of 45 male patients with documented
erectile dysfunction were enrolled in the study. Half of the patients
took ginseng tablets for 8 weeks (900 mg, three times per day), and
the other half took a placebo pill for 8 weeks. All patients were then
observed for 2 weeks without receiving either ginseng or placebo pills.
After this 2 week hiatus, the patients switched treatments, with the
prior ginseng group subsequently receiving placebo pills for 8 weeks.
The prior placebo pill group was also switched to ginseng for a period
of 8 weeks after the 2 week rest period. Using blood hormone levels,
patient surveys, a device that measures penile tip rigidity, and ultrasound
evaluations of the penis, the study’s authors concluded that the use
of ginseng significantly increased penis erectile function and rigidity.
In view of the many unsubstantiated health claims that have been made
for ginseng over the years, and the lack of sound scientific evidence
to support such claims, this study is highly interesting. Additional
studies, involving larger numbers of patients, should be performed to
confirm the findings of this small pilot study. However, ginseng could
prove to be a useful treatment for erectile dysfunction, either with
or without Viagra. It should also be noted that a number of new erectile
dysfunction drugs are about to hit the market. Most of them are chemically
similar to Viagra, but have been designed so as to enhance their effectiveness
while reducing the side effects associated with Viagra.
Viagra & Stroke
While I am on the subject of Viagra,
an interesting little study in the journal Stroke looked at the
effects of Viagra on rats that suffered strokes following surgical blockage
of the main artery feeding their brains. Scientists surgically blocked
the rats’ cerebral arteries and then administered Viagra to some of
the rats for a duration of 7 days, while the remaining rats received
only water. Surprisingly, the rats that were supplied with Viagra in
their drinking water made a significantly better neurological recovery,
following their strokes when compared to the rats that received water
only. While there was no difference in the size of the stroke between
the two groups of rats, a study of their brains revealed an increase
in the number of nerve cells in several regions of the brain among the
rats that had received Viagra. This fascinating study suggests a possible
role for Viagra in the treatment of acute strokes. Additional preliminary
studies will, of course, have to be performed in human patients who
have recently developed a stroke. If Viagra proves to have similar
beneficial effects on humans as it appeared to have on rats, then this
could be a very exciting breakthrough in the care of patients with strokes.
Dr.
Robert A. Wascher